GlaxoSmithKline returned rights to Wave Life Sciences’ lead RNA editing candidate for alpha‑1 antitrypsin deficiency (WVE‑006), leaving Wave to proceed independently and pursue accelerated approval pathways. Wave framed the handback as an opportunity to steer the program’s clinical strategy without partner constraints. Earlier coverage confirmed GSK’s decision to walk away from the collaboration, placing the development timeline and regulatory strategy back under Wave’s control. For the RNA editing field, the move highlights the transactional risks of early‑stage modality partnerships and the importance of sponsor alignment on clinical-development speed and regulatory strategy.